Valion Bio, Inc. (VBIO) intrinsic value & 10-year financials
Valion Bio, Inc. (VBIO) has a Graham intrinsic value of $557.59 per share. At $1.17 on Oct 17, 2026, the stock trades 100% below that value.
- Graham intrinsic value
- $557.59
- Share price (Oct 17, 2026)
- $1.17
- Price vs Graham value
- 100% below
- Market cap
- $336.2K
- Revenue (FY2025)
- —
- Revenue growth (6-yr CAGR)
- -14.7%
- ROIC (10-yr avg)
- -1229.3%
- Free cash flow (FY2025)
- -$7.0M
VBIO 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$8.9M | — | -$7.0M | — | -81.7% |
| FY2024 | $780.0K | -$5.7M | -$19.68 | -$5.7M | -725.8% | -1568.1% |
| FY2023 | $1.2M | -$8.2M | -$10.40 | -$8.6M | -701.1% | -1960.5% |
| FY2022 | $1.8M | -$10.1M | -$1.04 | -$8.9M | -548.8% | -1527.4% |
| FY2021 | $1.3M | -$8.5M | -$2.43 | — | -448.1% | -1008.8% |
| FY2020 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Valion Bio, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Valion Bio, Inc. has historically struggled to out-earn its cost of capital, averaging just -28.5% ROIC.
Valion Bio, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Valion Bio, Inc. is modeled at -14.7% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $557.59 per share.